It's not the news of the day because it was written in the Journal of Clinical Oncology in 2022. What came out today was a paper in the FASEB Journal that reviewed the progress of clinical trials of drugs targeted at GPCRs (G protein-coupled receptors) for cancer treatment; in that review they gave a shortened and far less positive recap of Leron's performance vs. TNBC.
So if you just read the paper that came out today, you'd think that Leron's results were a bit on the Meh side. But what they were quoting was a paper that acknowledged Leron's powerful abilities... two years ago.